Skip to main
RMD

ResMed (RMD) Stock Forecast & Price Target

ResMed (RMD) Analyst Ratings

Based on 10 analyst ratings
Hold
Strong Buy 0%
Buy 20%
Hold 80%
Sell 0%
Strong Sell 0%

Bulls say

ResMed is a leading respiratory care device company, with a focus on developing and supplying flow generators, masks, and accessories for the treatment of sleep apnea. The company is well-positioned in a structurally growing market, with increasing diagnosis of sleep apnea, aging populations, and rising rates of obesity. Recent developments and acquisitions in digital health indicate ResMed's focus on differentiation and expanding its market reach. Overall, the company's financials and growth potential, combined with its strategic initiatives, suggest a positive outlook for the stock.

Bears say

ResMed is facing challenges with its gross margin miss in 4Q26 and projections of a slight YoY contraction in gross margin in 1Q27, driven by inflation and higher freight costs. Additionally, the uncertainty surrounding the impact of GLP-1 drugs on the company's growth opportunities adds further concern to the long-term outlook. While the company's recent focus on digital health and potential market growth may seem promising, the negative financial trends and potential industry disruptors make for a challenging outlook.

ResMed (RMD) has been analyzed by 10 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 20% recommend Buy, 80% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of ResMed and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About ResMed (RMD) Forecast

Analysts have given ResMed (RMD) a Hold based on their latest research and market trends.

According to 10 analysts, ResMed (RMD) has a Hold consensus rating as of Aug 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $238.90, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $238.90, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

ResMed (RMD)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.